Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq:ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network to support and provide ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)”.
Related news for (ALIM)
- ani pharmaceuticals, inc. completes acquisition of alimera sciences
- ani pharmaceuticals initiates closing of acquisition of alimera sciences
- ani pharmaceuticals provides update on closing of acquisition of alimera sciences
- alimera sciences takes legal action against ani pharmaceuticals to enforce merger agreement
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®